SAN DIEGO, Sept. 18, 2026 /PRNewswire/ -- Robbins LLP reminds investors that a securities class action has been filed on behalf of all persons and entities that purchased or otherwise acquired Wise Group plc (NASDAQ: WSE) securities between May 11, 2026 and July 23, 2026 (the "Class Period").

The complaint alleges that Wise and certain of its senior executives violated the federal securities laws by making materially false and/or misleading statements regarding the Company's anti-money laundering compliance, anti-terrorist financing controls, and regulatory risks.

Investors who suffered losses during the Class Period may have legal rights. If you want to seek appointment as lead plaintiff, you must submit your papers to the court by September 28, 2026.

Listen to our podcast.

Why Was Wise Group Sued?

Wise is a global financial technology company that provides international money transfer and cross-border payment services. On May 11, 2026, the Company transferred its primary stock listing from the London Stock Exchange to the Nasdaq Global Select Market under the ticker symbol "WSE."

According to the complaint, defendants sought to portray Wise as well-positioned for growth in the United States while allegedly failing to disclose material regulatory issues affecting the Company's business. The lawsuit alleges that, at the time of its Nasdaq listing and related SEC filings, Wise materially understated the regulatory risks facing the Company arising from allegedly deficient anti-money laundering and counter-terrorist financing controls.

Specifically, the complaint alleges that defendants failed to disclose that:

- Wise allegedly faced significant regulatory risks arising from materially deficient anti-money laundering controls and anti-terrorist financing procedures;

- the Company allegedly was under an active investigation by Belgian authorities concerning potential money laundering offenses;

- Wise allegedly faced a materially greater risk that the Office of the Comptroller of the Currency ("OCC") would deny its application for a U.S. national trust bank charter due to longstanding compliance deficiencies; and

- as a result, defendants' statements concerning the Company's business, regulatory compliance, and future prospects were materially false and misleading or lacked a reasonable basis.

Why Did WSE Stock Decline?

According to the complaint, on June 1, 2026, Reuters reported that the Brussels Public Prosecutor's Office was investigating Wise Europe in connection with transactions reportedly involving more than €500 million in suspicious activity. The article stated that prosecutors were investigating potential money laundering offenses with alleged links to fraud, corruption, and drug trafficking. The complaint alleges that following this news, Wise's U.S.-listed shares declined from $12.77 to $10.72 over the course of three trading days.

The lawsuit further alleges that on July 24, 2026, additional information reached the market when reports disclosed that the OCC had denied Wise's application for a national trust bank license. According to the complaint, the OCC cited significant supervisory and compliance concerns, including longstanding deficiencies in Wise U.S.'s anti-money laundering and counter-terrorist financing program. Following this disclosure, Wise's U.S.-listed shares fell an additional 6.2%, closing at $11.33 per share on July 24, 2026.

What Is a Lead Plaintiff?

The lead plaintiff is the investor appointed by the court to represent the interests of the proposed class throughout the litigation. If you want to become the lead plaintiff, you must file your papers with the court by September 28, 2026. Investors do not have to serve as lead plaintiff to potentially share in any recovery if the lawsuit is successful.

Does It Cost Anything to Participate?

No. Robbins LLP represents investors on a contingency fee basis. Investors never pay attorneys' fees or litigation expenses. If there is a recovery, defendants pay fees and costs.

Why Robbins LLP?

A recognized leader in shareholder rights litigation, Robbins LLP has helped restore more than $2 billion in value to shareholders and secured some of the largest recoveries in shareholder derivative litigation history.

"Behind everything we do is the belief that companies should be governed responsibly, fiduciaries should be held accountable, and shareholders deserve transparency and fairness," said Brian J. Robbins, Founding Partner of Robbins LLP.

To be notified if a class action against Wise Group plc settles or to receive free alerts when corporate executives engage in wrongdoing, sign up for Stock Watch today.

Contact Robbins LLP

Investors seeking additional information about the Wise Group plc securities class action may submit an inquiry through Robbins LLP's website, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003.

Attorney Advertising. Past results do not guarantee a similar outcome.

SOURCE Robbins LLP

Share this article

Corgi Insurance Appoints Daniel Hausman as Vice President of Trucking Program

ATLANTA, Sept. 18, 2026 /PRNewswire/ -- Corgi Insurance, an AI-native insurance carrier, has announced the appointment of Daniel Hausman as Vice President of its Trucking Program, bringing decades of experience in commercial trucking insurance, underwriting, program development, distribution, and risk management to Corgi's transportation business.

Hausman is an accomplished insurance professional with deep expertise in commercial trucking risk and a track record of building and scaling insurance programs from the ground up. He holds a CPCU, MBA, and Lean Six Sigma Green Belt, combining technical underwriting discipline with practical knowledge of the transportation industry.

Before joining Corgi, Hausman helped scale CSMV Underwriters from zero to nearly $20 million in one year. He also served as the first Non-Fleet Business Development Manager at Nirvana, where he helped build and scale the program from zero to $30 million. His work included rates and rules, forms redesign, go-to-market strategy, distribution, broker-of-record guidelines, customer complaint resolution, production incentives, and broader program development.

At Transportation Insurance Experts (TIE), Hausman helped negotiate a more favorable capacity agreement for its Knight Specialty binding contract and expanded distribution, contributing to 180% year-over-year profitable growth. He also led underwriting and compliance audits that resulted in updated rules and guidelines and streamlined the company's monthly data reporting processes.

Hausman has also held operational leadership roles during corporate restructurings and led the strategic acquisition of Mulligan AI, a YC-backed insurtech focused on automating the insurance agent experience in the trucking industry.

Hausman brings an extensive network across the trucking insurance ecosystem, including retail and direct-to-consumer distribution, MGAs, carriers, embedded distribution partners, vendors, and transportation businesses.

"Hausman has spent his career understanding what makes trucking insurance work, from underwriting and capacity to distribution and operations," said Emily Yuan, COO of Corgi. "His experience building programs at scale makes him a natural fit to help Corgi continue developing insurance products for the transportation industry."

About Corgi Insurance

Corgi Insurance is an AI-native, full-stack insurance carrier building a new generation of commercial insurance. Founded by Emily Yuan and Nico Laqua, Corgi combines insurance expertise with AI and modern technology to make coverage faster, smarter, and more accessible. Corgi offers insurance across a growing range of industries and risks while building the technology and infrastructure to modernize the insurance lifecycle.

Media Contact:

Erika Lee

[email protected]

SOURCE Corgi

Share this article

NASHVILLE, Tenn., Sept. 18, 2026 /PRNewswire/ -- Award-winning independent music duo The Swansons mark a significant season with the release of their powerful new single, "Hey God, It's Me Again," and four nominations for the upcoming Josie Music Awards. The husband-and-wife duo will attend the ceremony at the legendary Grand Ole Opry on Sunday, September 20, in Nashville.

Listeners are invited to celebrate this milestone by streaming "Hey God, It's Me Again" at https://ffm.to/hey-god-its-me-again and following their journey to the awards.

The Swansons received nominations in four distinct categories:

- Album of the Year — Seven

- Song of the Year — "Pray"

- Song of the Year — "Stick & Stones"

- Duo of the Year

These nominations underscore a meaningful chapter for The Swansons, whose music consistently reflects their shared journey, faith, marriage, and dedication to connecting with listeners through honest, heartfelt songwriting.

Their latest release, "Hey God, It's Me Again," continues this tradition. The song presents a deeply personal message, exploring the everyday conversations people have with God—moments of uncertainty, gratitude, hope, and the universal need for connection.

For The Swansons, their musical endeavor extends beyond song creation. It centers on sharing stories, offering encouragement, and forging connections with audiences through their unique perspective as life and music partners.

The Swansons state, "We're incredibly grateful for this season. Having four nominations alongside the release of our new single makes this a very special time for us. We're honored to be recognized among so many talented independent artists, and we're excited to head to Nashville, celebrate with our fellow musicians, and enjoy the experience together."

The Josie Music Awards annually recognize independent music artists and industry professionals, bringing together musicians from across the country to celebrate independent music.

With four nominations, a brand-new single, and another chapter unfolding in their musical story, The Swansons head to Nashville with grateful hearts and a song to share.

About

The Swansons are a husband-and-wife music duo bringing heart, harmony, and a shared love of music to every performance. Blending soulful vocals, heartfelt songwriting, and undeniable chemistry, the duo creates a sound that feels both intimate and timeless.

Built on a genuine partnership both on and off the stage, The Swansons connect with audiences through songs that tell stories of love, life, faith, family, and the experiences that shape us. Their performances combine warm vocal harmonies with an engaging, down-to-earth presence that makes every room feel a little more personal.

Whether performing an intimate acoustic set, a full evening of live music, or an original song, The Swansons bring authenticity and emotion to everything they do.

Two voices. One story. A lifetime of music together.

SOURCE TSM Group LLC

Share this article

SAN DIEGO, Sept. 18, 2026 /PRNewswire/ -- Robbins LLP reminds investors that a securities class action has been filed on behalf of all persons and entities that purchased or otherwise acquired Bloom Energy Corporation (NYSE: BE) securities between February 27, 2025 and July 8, 2026 (the "Class Period"). Bloom Energy designs, manufactures, sells, and installs solid oxide fuel cell systems for on-site power generation in the United States and internationally. Scandium is a rare earth metal used as a dopant to stabilize the zirconia-based ceramic electrolyte in the Company's solid oxide fuel cells.

The lawsuit alleges that Bloom Energy misled investors regarding the source of its materials.

Investors who suffered losses during the Class Period may have legal rights. The deadline to seek appointment as lead plaintiff is September 28, 2026.

Listen to our podcast.

Why Was Bloom Energy Sued?

According to the complaint, Bloom Energy described the Company's supply chain as not being dependent on China. The lawsuit alleges that Bloom Energy and certain defendants failed to adequately disclose that the Company was in fact reliant on Chinese scandium.

According to plaintiff, defendants failed to disclose that:

(1) Bloom Energy obtained scandium through intermediaries who sourced the metal from China;

(2) the Company understated the extent to which it relied on scandium from China; and

(3) as a result, defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

Why Did BE Stock Collapse?

This complaint alleges that the collapse of Bloom Energy's stock followed the publication of an article by Hunterbrook Media entitled "Bloom's Big Lie." The Report alleged that Bloom Energy is "in fact, reliant on Chinese scandium."

Hunterbrook "found four separate trade routes that appear to show Chinese scandium is still part of Bloom's supply chain, and the material is reaching the U.S. through intermediary countries." Based on conversations with a major scandium producer in China (who claimed to be Bloom Energy's largest supplier) and commercially available trade data, the Report claimed that Bloom Energy received scandium directly from China on 4 occasions between August 2023 and May 2024."

On this news, Bloom's stock price fell $15.28, or 5.7%, to close at $254.29 per share on July 8, 2026.

What Is a Lead Plaintiff?

The lead plaintiff is the investor appointed by the court to represent the interests of the proposed class throughout the litigation. If you are interested in seeking appointment as lead plaintiff, you must submit your papers with the court by September 28, 2026. Investors do not have to serve as lead plaintiff to potentially share in any recovery if the lawsuit is successful.

Does It Cost Anything to Participate?

No. Robbins LLP represents investors on a contingency fee basis.

Why Robbins LLP?

A recognized leader in shareholder rights litigation, Robbins LLP has helped restore more than $1 billion in value to shareholders and secured some of the largest recoveries in shareholder derivative litigation history.

"Behind everything we do is the belief that companies should be governed responsibly, fiduciaries should be held accountable, and shareholders deserve transparency and fairness," said Brian J. Robbins, Founding Partner of Robbins LLP.

To be notified if a class action against Bloom Energy Corporation settles or to receive free alerts when corporate executives engage in wrongdoing, sign up for Stock Watch today.

Contact Robbins LLP

Investors seeking additional information about the Bloom Energy securities class action may submit an inquiry through Robbins LLP's website, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003.

Attorney Advertising. Past results do not guarantee a similar outcome.

SOURCE Robbins LLP

Share this article

SAN DIEGO, Sept. 18, 2026 /PRNewswire/ -- Robbins LLP informs investors that a securities class action has been filed on behalf of all persons and entities that purchased or otherwise acquired Capricor Therapeutics, Inc. (NASDAQ: CAPR) securities between December 17, 2025 and July 26, 2026 (the "Class Period").

The lawsuit alleges that Capricor Therapeutics misled investors regarding the path to FDA approval for its lead product candidate Deramiocel, a cell therapy to address cardiac and skeletal muscle complications associated with Duchenne muscular dystrophy.

Investors who suffered losses during the Class Period may have legal rights and should contact Robbins LLP for information about seeking appointment as lead plaintiff before the September 28, 2026 deadline.

Listen to our podcast.

Why Was Capricor Therapeutics Sued?

Capricor is a biotechnology company focused on developing cell and exosome-based therapeutics for rare diseases, including Duchenne muscular dystrophy ("DMD"). The Company's lead product candidate is Deramiocel, an investigational cell therapy intended to address cardiac and skeletal muscle complications associated with DMD.

According to the complaint, Capricor submitted a Biologics License Application ("BLA") to the U.S. Food and Drug Administration ("FDA") for Deramiocel in late 2024. In July 2025, the FDA issued a Complete Response Letter stating that the BLA did not meet the statutory requirement for substantial evidence of effectiveness and requesting additional clinical data.

The complaint alleges that, during the Class Period, Capricor made positive statements regarding the clinical results for Deramiocel and the prospects for FDA approval while failing to disclose material information concerning changes to the pre-specified statistical analysis plan ("SAP") used to analyze clinical data from the Phase 3 HOPE-3 trial.

Specifically, the complaint alleges that defendants failed to disclose that:

(1) the Company adopted changes to the pre-specified statistical analysis plan used to analyze clinical data for Deramiocel;

(2) the FDA did not agree to those changes before the Company resubmitted the Deramiocel BLA;

(3) there was a significant risk that the FDA could conclude the clinical results did not provide substantial evidence of effectiveness of Deramiocel;

(4) as a result, there was a substantial risk to regulatory approval of Deramiocel for the treatment of Duchenne muscular dystrophy; and

(5) therefore, defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

Why did CAPR's Stock Drop 64%?

According to the complaint, following the FDA disclosures on July 27, 2026, Capricor's stock price fell $12.70 per share, or approximately 64%, to close at $7.00 per share.

On July 29, 2026, the FDA advisory committee met to discuss the Deramiocel BLA. According to the complaint, the following day Medscape reported that the advisory committee relied on SAP version 1.1 as the "prespecified plan" and, in a non-binding 9-3 vote, concluded that the available evidence did not support the efficacy of Deramiocel for treating DMD-associated cardiomyopathy.

The complaint alleges that, following this news, Capricor's stock price fell another $2.38 per share, or approximately 36%, to close at $4.19 per share on July 30, 2026.

What Is a Lead Plaintiff?

The lead plaintiff is the investor appointed by the court to represent the interests of the proposed class throughout the litigation. Shareholders who wish to seek appointment as lead plaintiff must do so prior to September 28, 2026. Investors do not have to serve as lead plaintiff to potentially share in any recovery if the lawsuit is successful.

Does It Cost Anything to Participate?

No. Robbins LLP represents investors on a contingency fee basis.

Why Robbins LLP?

A recognized leader in shareholder rights litigation, Robbins LLP has helped restore more than $2 billion in value to shareholders and secured some of the largest recoveries in shareholder derivative litigation history.

"Behind everything we do is the belief that companies should be governed responsibly, fiduciaries should be held accountable, and shareholders deserve transparency and fairness," said Brian J. Robbins, Founding Partner of Robbins LLP.

To be notified if a class action against Capricor Therapeutics, Inc. settles or to receive free alerts when corporate executives engage in wrongdoing, sign up for Stock Watch today.

Contact Robbins LLP

Investors seeking additional information about the Capricor Therapeutics, Inc. securities class action may submit an inquiry through Robbins LLP's website, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003.

Attorney Advertising. Past results do not guarantee a similar outcome.

SOURCE Robbins LLP

Share this article

NEW YORK, Sept. 18, 2026 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Taboola.com Ltd. (NASDAQ: TBLA) between May 6, 2026 and August 4, 2026, both dates inclusive (the "Class Period"), of the important October 20, 2026 lead plaintiff deadline.

So what: If you purchased Taboola.com securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

What to do next: To join the Taboola.com class action, go to https://rosenlegal.com/cases/taboolacom-ltd/join or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than October 20, 2026. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

Why Rosen Law: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually handle securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered billions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.

Details of the case: According to the lawsuit, throughout the Class Period, defendants made materially false and misleading statements and/or failed to disclose that: (1) Taboola.com was seeing an increase in low-quality publishers; (2) as a result, Taboola.com would need to take an aggressive approach to exiting these low-quality publisher relationships, impacting earnings; (3) as a result, the value of Taboola.com's publisher relationships was overstated; and (4) as a result of the foregoing, defendants' positive statements about Taboola.com's business, operations, and prospects were materially misleading and/or lacked a reasonable basis. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the Taboola.com class action, go to https://rosenlegal.com/cases/taboolacom-ltd/join or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:

     Laurence Rosen, Esq.

     Phillip Kim, Esq.

     The Rosen Law Firm, P.A.

     275 Madison Avenue, 40th Floor

     New York, NY 10016

     Tel: (212) 686-1060

     Toll Free: (866) 767-3653

     Fax: (212) 202-3827

     [email protected]

     www.rosenlegal.com

SOURCE THE ROSEN LAW FIRM, P. A.

Share this article

CIRCA RESORT & CASINO AND CIRCA SPORTS ANNOUNCED AS A'S FIRST FOUNDING PARTNER

Multi-year partnership brings together the A's, Circa and Circa Sports to create new fan, hospitality and community experiences

Circa named as Official Resort and Sportsbook of the Athletics

LAS VEGAS, Sept. 18, 2026 /PRNewswire/ -- The Las Vegas Athletics announced a multi-year partnership with Circa Resort & Casino and Circa Sports, naming the organization as the Club's first Founding Partner, marking a major milestone as the A's establish their presence in Las Vegas and build toward the opening of its new ballpark in 2028. Circa and Circa Sports will become an Official Resort and Sportsbook of the Las Vegas Athletics and the Las Vegas Athletics Ballpark, as well as an Official Founding Partner of the A's.

"Circa represents so much of what makes Las Vegas special – its energy, its commitment to creating unforgettable experiences and its deep connection to the sports community," said Marc Badain, president of the Athletics. "Derek and his team have been great partners, supporting the Club in West Sacramento during our time there, and we're excited to build on that relationship. As we look toward the opening of the A's ballpark, having Circa as our first Founding Partner is an important step in bringing our vision for a uniquely Las Vegas experience to life."

Derek Stevens, CEO of Circa and Circa Sports, said, "I've been a baseball fan my entire life, and I've long believed that MLB belongs in Las Vegas. To do it as the A's first Founding Partner is incredibly special. This is bigger than creating a great time inside the ballpark. It's about welcoming baseball to Las Vegas, giving this community something new to rally around and creating the kind of unforgettable experiences this city does better than anywhere else."

At the center of the partnership will be the Circa Dugout Box, a premium hospitality experience putting guests alongside the action, connected directly to the A's dugout. The exclusive space offers an intimate, high-energy environment unlike a traditional suite or premium seating area, giving guests an up-close connection to the action on the field.

Circa will also introduce the "Time of Your Life" seats, available exclusively through property hotel packages. The offering will connect a stay at the downtown Las Vegas resort with a night at the ballpark.

Additional details will be announced soon.

SOURCE Circa Resort & Casino

Share this article

NEW YORK, Sept. 18, 2026 /PRNewswire/ -- Greenberg Traurig, LLP Shareholders Lori G. Cohen and Mathew Rosengart have been named to Forbes' 2026 America's Top Lawyers list. Cohen, vice chair of the firm and co-chair of its Global Litigation Practice and Trial Practice Group, was recognized for the second consecutive year. Rosengart, co-chair of the firm's National Media & Entertainment Litigation Practice, was recognized for the third consecutive year, beginning with Forbes' inaugural 2024 list of the Top 200 Lawyers in America.

The annual list highlights attorneys across practice areas, including dealmakers, litigators, advisers, and strategists. According to Forbes, honorees are selected through a rigorous multistage process that considers nominations, research, peer recommendations, and editorial review.

Known nationally for a record of 58 defense verdicts, Cohen focuses on complex products liability, pharmaceutical, medical device, and health care litigation. She serves as national, regional, and trial counsel for major medical device and pharmaceutical manufacturers in class actions, multidistrict litigation, and trials nationwide. She also built the firm's Pharmaceutical, Medical Device & Health Care Litigation Practice, which includes more than 100 attorneys across more than 30 offices. Her additional honors include selections by The American Lawyer, Chambers USA, The Legal 500, The Best Lawyers in America, and Georgia Super Lawyers. Benchmark Litigation recently presented Cohen with its Hall of Fame Award, and she was named The American Lawyer's 2024 Attorney of the Year.

Rosengart, a Chambers USA-ranked former federal prosecutor and Justice Department trial attorney, handles high-stakes media, entertainment, commercial, and white collar matters for prominent individuals and companies across the entertainment, media, technology, and corporate sectors. Rosengart's many other honors include selections by The Legal 500 and Best Lawyers in America, being named Benchmark Litigation's Entertainment Litigator of the Year in both 2024 and 2025, one of Lawdragon's 500 Leading Litigators in America, a Litigation Trailblazer by The National Law Journal, Litigator of the Week by The American Lawyer, and a Media & Entertainment MVP by Law360. He has also routinely been selected as one of California's and Los Angeles' Top 100 attorneys by the Daily Journal and the Los Angeles Business Journal, respectively. Forbes previously described Rosengart as an "elite" and "revered" litigator.

About Greenberg Traurig: Greenberg Traurig, LLP has approximately 3,200 lawyers across 51 locations in the United States, Europe, the Middle East, Latin America, and Asia. The firm's broad geographic and practice range enables the delivery of innovative and strategic legal services across borders and industries. Recognized as a 2025 BTI "Best of the Best Recommended Law Firm" by general counsel for trust and relationship management, Greenberg Traurig is consistently ranked among the top firms on the Am Law Global 100, NLJ 500, and Law360 400. Greenberg Traurig is also known for its philanthropic giving, culture, innovation, and pro bono work. Web: www.gtlaw.com.

SOURCE Greenberg Traurig, LLP

Share this article

ROCHESTER, Mich., Sept. 18, 2026 /PRNewswire/ -- Par Health is voluntarily recalling two lots of Dexmedetomidine HCl in 0.9% Sodium Chloride Injection 400 mcg/100 mL (4 mcg/mL) to the hospital level. The product is being recalled due to the presence of particulate matter identified as cellulose or stopper material.

Administration of Dexmedetomidine HCl in 0.9% Sodium Chloride Injection 400 mcg/100 mL, found to contain particulate matter, has a reasonable probability of causing life-threatening adverse health consequences including pulmonary emboli (blockage in pulmonary blood vessels), occlusions of other blood vessels (which can lead to tissue death and possible organ damage), and/or inflammation of the walls of veins, which may lead to clotting. To date, Par Health has not received any reports of adverse events related to this recall.

Dexmedetomidine HCl in 0.9% Sodium Chloride Injection 400 mcg/100 mL (4 mcg/mL) is formulated for intravenous infusion. The product is indicated for sedation of initially intubated and mechanically ventilated adult patients during treatment in an intensive care setting and for sedation of non-intubated adult patients prior to and/or during surgical and other procedures.

Recalled product can be identified as follows and by vial label images included with this release:

These lots were distributed nationwide to wholesalers between May 13, 2025 and June 29, 2025.

Par Health is providing written notification to wholesale accounts that have received the affected lots and are arranging for return of all existing inventory of Lots 87558 and 88802 through Inmar, Inc. Wholesale distributors and hospital pharmacies that have the product being recalled should immediately discontinue use and stop distribution. If you have further distributed the recalled product, please notify your accounts or any additional locations which may have received the recalled product.

Questions regarding this recall can be directed to Inmar, Inc. at 1-833-599-3197 Monday through Friday between the hours of 9 a.m. and 5 p.m. ET or by email at [email protected].

For medical or technical product information or to report a product complaint or adverse event please call 1-800-828-9393 Monday through Thursday between the hours of 9 a.m. and 8 p.m. ET or Friday between 9 a.m. and 6 p.m. ET.

Adverse reactions or quality problems experienced with the use of this product may be reported to the FDA's MedWatch Adverse Event Reporting program either online, by regular mail or by fax.

- Complete and submit the report Online: www.fda.gov/medwatch/report.htm

- Regular Mail or Fax: Download form www.fda.gov/MedWatch/getforms.htm or call 1-800-332-1088 to request a reporting form, then complete and return to the address on the pre-addressed form, or submit by fax to 1-800-FDA-0178

This recall is being conducted with the knowledge of the U.S. Food and Drug Administration.

Contacts

Gena Holthaus, Senior Director, Corporate Brand and Communications

[email protected]

SOURCE Par Health

Share this article

NEW YORK, Sept. 18, 2026 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Hyliion Holdings Corp. (NYSE American: HYLN) between May 12, 2026 and June 23, 2026, both dates inclusive (the "Class Period"), of the important October 27, 2026 lead plaintiff deadline.

So what: If you purchased Hyliion securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

What to do next: To join the Hyliion class action, go to https://rosenlegal.com/cases/hyliion-holdings-corp/join or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than October 27, 2026. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

Why Rosen Law: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually handle securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered billions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.

Details of the case: According to the lawsuit, defendants made false and/or misleading statements and/or omitted material facts concerning the credibility of its announced commercial pipeline, notably, the basis for management's confidence in its VFG Holdings ("VFG") partnership and the extent of Hyliion's evaluation of VFG's operational capabilities, financial resources, and ability to perform before announcing the "new data center partnership" as a significant commercial opportunity. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the Hyliion class action, go to https://rosenlegal.com/cases/hyliion-holdings-corp/join or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:

     Laurence Rosen, Esq.

     Phillip Kim, Esq.

     The Rosen Law Firm, P.A.

     275 Madison Avenue, 40th Floor

     New York, NY  10016

     Tel: (212) 686-1060

     Toll Free: (866) 767-3653

     Fax: (212) 202-3827

     [email protected] 

     www.rosenlegal.com

SOURCE THE ROSEN LAW FIRM, P. A.

Share this article